Asia Pacific Biodefense Market to Grow at a CAGR of 9.8% to reach US$ 723.70 Million from 2020 to 2027

Asia Pacific Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography

Publication Month: Apr 2020 | Report Code: TIPRE00010409 | No. of Pages: 100 | Category: Biotechnology | Status: Published
Covid

The Asia Pacific Biodefense market is expected to reach US$ 723.70 Mn in 2027 from US$ 1,520.67 Mn in 2019. The market is estimated to grow with a CAGR of 9.8% from 2019-2027.

 

The growth of the Biodefense Market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Asia Pacific region. However, low R&D funding by government in developing and underdeveloped economies is likely to restrain the market growth to a certain extent.

 

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

 

Disease outbreaks of emerging infectious diseases are infections that have recently appeared within a population and are rapidly increasing or threaten to grow shortly. The SARS 2002-2003 epidemic appeared in November 2002 in the Guangdong province of southern China. This area is considered as a potential zone of re-emergence of SARS-CoV. Again, Human infections with an Asian lineage avian influenza A(H7N9) virus (“Asian H7N9”) were first reported in China in March 2013. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the market development. On 15 January 2020, the Ministry of Health, Labour and Welfare, Japan (MHLW) reported an imported case of laboratory-confirmed 2019-novel coronavirus (2019-nCoV) from Wuhan, Hubei Province, China. As of 30 March, 2020 Japan, reported 1,866 confirmed cases along with 74 deaths. Further, as of April 2020, China has approved three COVID-19 vaccine submissions for clinical trials, state-run Xinhua news agency quoted a Ministry of Science and Technology official.

The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense Market growth.

Biological weapons (BWs) deliver toxins and microorganisms, such as viruses and bacteria, so as to intentionally inflict disease among people, animals, and agriculture. Biological attacks can result in destruction of crops, temporarily discomforting a small community, killing large numbers of people, or other outcomes. Biological weapons have a long history of use. In 1346, the invading Tartar army catapulted the bodies of plague victims into the Crimean Peninsula city of Kaffa and infected its citizens. In 1763, British troops under General Jeffrey Amherst gave the Delaware Indians blankets used by people with smallpox, possibly infecting the susceptible native population. Japan contaminated food and released plague-infected ticks during their conflict with China during World War II.  Although recent advances in biotechnology have made it easier to develop dangerous viruses, bacteria, and toxins with fewer resources. This has increased concerns that individuals and groups could resort to bioterrorism to attack a population. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the Asia Pacific Biodefense Market.

 

Rest of Asia Pacific Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Rest of Asia Pacific Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Get more information on this report :


ASIA PACIFIC BIODEFENSE MARKET– MARKET SEGMENTATION

Asia Pacific Biodefense Market – By Product

  • Anthrax
  • Small pox
  • Botulism
  • Radiation/Nuclear
  • Others

Asia Pacific Biodefense Market – By Country

  • Japan
  • China
  • India
  • South Korea
  • Australia

Companies Mentioned

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • Pluristem Therapeutics

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Asia Pacific Biodefense market – By Product

1.3.2        Asia Pacific Biodefense market – By Country

2.           Asia Pacific Biodefense market –  Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Asia Pacific Biodefense market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        4.2.1 Biodefense market - Asia Pacific PEST Analysis

4.3         Expert Opinion

5.           Asia Pacific Biodefense market -  Key Market Dynamics

5.1         Key Market Drivers

5.1.1        Presence of Favourable Government Initiatives

5.1.2        Increase in the Number of Naturally Occurring Outbreaks

5.1.3        Increasing Threat of Biological Weapons and Nuclear Armed ICBM

5.2         Key Market Restraints

5.2.1        Low R&D Funding by Government in Developing and Underdeveloped Economies

5.3         Key Market Opportunities

5.3.1        Increased Adoption of Technologies

5.4         Future Trends

5.4.1        Predictive Analytics to Reshape Biodefense Market

5.5         Impact Analysis

6.           Biodefense market – Asia Pacific Analysis

6.1         Asia Pacific Biodefense market Revenue Forecasts and Analysis

7.           Asia Pacific Biodefense market Analysis And Forecasts To 2027 – By Product

7.1         Overview

7.2         Asia Pacific Biodefense market, By Product 2019 & 2027 (%)

7.2.1        Asia Pacific Biodefense market Revenue and Forecasts to 2027, By Product (US$ Mn)

7.3         Anthrax

7.3.1        Overview

7.3.2        Asia Pacific Anthrax Market Revenue and Forecast to 2027 (US$ Mn)

7.4         Small pox

7.4.1        Overview

7.4.2        Asia Pacific Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

7.5         Botulism

7.5.1        Overview

7.5.2        Asia Pacific Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

7.6         Radiation/Nuclear

7.6.1        Overview

7.6.2        Asia Pacific Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.           Biodefense market Revenue and Forecasts To 2027 – Geographical Analysis

8.1         Asia Pacific Biodefense market Revenue and Forecasts To 2027

8.1.1        Overview

8.1.2        Asia Pacific: Biodefense Market - Revenue and Forecast to 2027 (USD Million)

8.1.3        Asia Pacific: Biodefense Market, by Product, 2018–2027 (USD Million)

8.1.4        Asia Pacific: Biodefense Market, by Country, 2018 & 2027 (%)

8.1.5        China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.1          China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.2          China: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.6        Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.1          Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.2          Japan: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.7        India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.1          India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.2          India: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.8        South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.1          South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.2          South Korea: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.9        Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.1          Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.2          Australia: Biodefense Market, by Product Type, 2018–2027 (USD Million)

9.           Impact of Covid-19 Pandemic On Asia Pacific Biodefense Market

9.1         Asia-Pacific: Impact assessment of COVID-19 Pandemic

10.        Asia Pacific Biodefense market Industry Landscape

10.1      Overview

10.2      Growth Strategies in The Biodefense Market, 2016-2020

10.3      Inorganic Growth Strategies

10.3.1     Overview

10.4      Organic Growth Strategies

10.4.1     Overview

11.        COMPANY PROFILES

11.1      Bavarian Nordic

11.1.1     Key Facts

11.1.2     Business Description

11.1.3     Products and Services

11.1.4     Financial Overview

11.1.5     SWOT Analysis

11.1.6     Key Developments

11.2      Alnylam Pharmaceuticals, Inc.

11.2.1     Key Facts

11.2.2     Business Description

11.2.3     Products and Services

11.2.4     Financial Overview

11.2.5     SWOT Analysis

11.2.6     Key Developments

11.3      SIGA Technologies

11.3.1     Key Facts

11.3.2     Business Description

11.3.3     Products and Services

11.3.4     Financial Overview

11.3.5     SWOT Analysis

11.3.6     Key Developments

11.4      Emergent BioSolutions Inc.

11.4.1     Key Facts

11.4.2     Business Description

11.4.3     Products and Services

11.4.4     Financial Overview

11.4.5     SWOT Analysis

11.4.6     Key Developments

11.5      Cleveland Bio Labs

11.5.1     Key Facts

11.5.2     Business Description

11.5.3     Products and Services

11.5.4     Financial Overview

11.5.5     SWOT Analysis

11.5.6     Key Developments

12.        Appendix

12.1      About The Insight Partners

12.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Asia Pacific Biodefense market Revenue and Forecasts To 2027, By Product (US$ Mn)

Table 2.             Asia Pacific Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 3.             China Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 4.             Japan Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 5.             India Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 6.             South Korea Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 7.             Australia Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 8.             Recent Inorganic Growth Strategies In The Biodefense Market

Table 9.             Recent Organic Growth Strategies In The Biodefense Market

Table 10.          Glossary of Terms, Skin aesthetic devices market

 


LIST OF FIGURES

Figure 1.           Biodefense market Segmentation

Figure 2.           Asia Pacific Biodefense market Overview

Figure 3.           Anthrax Segment Held Largest Share of Product Segment in Biodefense Market

Figure 4.           Japan is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Asia Pacific Biodefense market- Leading Country Markets (US$ Mn)

Figure 6.           Asia Pacific Biodefense market, Industry Landscape

Figure 7.           Biodefense market - Asia Pacific PEST Analysis

Figure 8.           Biodefense market Impact Analysis of Drivers and Restraints

Figure 9.           Asia Pacific Biodefense market – Revenue Forecasts and Analysis – 2019- 2027

Figure 10.        Asia Pacific Biodefense market, By Product 2019 & 2027 (%)

Figure 11.        Asia Pacific Anthrax Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Asia Pacific Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        Asia Pacific Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Asia Pacific Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Asia Pacific: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

Figure 17.        Asia Pacific Biodefense Market Revenue and Forecast to 2027 (USD Million)

Figure 18.        China: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 19.        Japan: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 20.        India: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 21.        South Korea: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 22.        Australia: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 23.        Impact Of Covid-19 Pandemic In Asia Pacific Country Markets

Figure 24.        Growth Strategies in the Biodefense Market, 2016-2020

 

The List of Companies - Asia Pacific Biodefense Market

  1. Bavarian Nordic
  2. Alnylam Pharmaceuticals, Inc.
  3. SIGA Technologies
  4. Emergent BioSolutions Inc.
  5. Cleveland Bio Labs
  6. Dynavax Technologies
  7. Elusys Therapeutics, Inc.
  8. Soligenix
  9. Altimmune
  10. Pluristem Therapeutics
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific biodefense market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

TIPRE00010409
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing